Introduction to the ExoDx Prostate Test + mpMRI
The clinical question before us is how do we enable the best balance, helping to increase compliance with the biopsy recommendation for patients at higher-risk while providing greater assurance for low-risk patients in an informed shared decision to defer biopsy? There is a vital need to understand better how mpMRI and the various biomarkers can be integrated into the prostate cancer diagnostic algorithm.
Here, we review the potential strengths and limitations of multiparametric magnetic resonance imaging (mpMRI) and how biomarkers, specifically the ExoDx Prostate (EPI) Test might be considered, in combination with imaging, to provide the most informed decision-making.
Potential clinical strategies for combining the ExoDx Prostate Test and multiparametric magnetic resonance imaging (mpMRI). Using the ExoDx Prostate Test either before or after mpMRI are possible approaches for layered risk assessment and more informed decision-making.